Target Health Resources

Pfizer and Protalix to Develop and Commercialize Treatment for Gaucher’s Disease

December 5, 2009




Target Health was Protalix’s CRO partner and together with Cato Israel, who monitored outside of North America, we took this product from toxicology to the pre-IND meeting, IND submission, Phase I, Phase III, Orphan Drug, Fast Track, Expanded Access, multiple FDA meetings and now the eCTD NDA submission.

Download Now

Contact Target Health

Reach out today and let us know how we can help you!
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form